PONATINIB BDBM50322535 US9255107, AP24534 US10464902, Ponatinib 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide CHEMBL1171837 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide
- Kaiser, TM; Dentmon, ZW; Dalloul, CE; Sharma, SK; Liotta, DC Accelerated Discovery of Novel Ponatinib Analogs with Improved Properties for the Treatment of Parkinson's Disease. ACS Med Chem Lett 11: 491-496 (2020)
- Liu, Y; Peng, X; Guan, X; Lu, D; Xi, Y; Jin, S; Chen, H; Zeng, L; Ai, J; Geng, M; Hu, Y Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors. Eur J Med Chem 126: 122-132 (2017)